Close

CPIC® Guideline for Fluoropyrimidines and DPYD

Most recent guideline publication:

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017)

Updates since publication:

No updates on dosing recommendations since 2017 publication.

Tables provided in the main manuscript of the guideline:

Table 1. Assignment of likely DPD phenotype based on DPYD genotype
Table 2. Recommended dosing of fluoropyrimidines by DPD phenotype

Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017)

Tables included in the supplement or referenced in the guidelinea:

Supplemental Table S1. Evidence linking DPYD genotype with DPD phenotype and dihydropyrimidine toxicity
DPYD allele functionality table 
DPYD frequency table 
DPYD genotype-phenotype table 

Gene resource mapping

DPYD gene resource mapping 

Drug resource mapping

5-fluorouracil

Capecitabine

Clinical decision supportb:

Fluoropyrimidines pre- and post-test alerts and flow chart 

aSome of the tables included in the guideline may have been updated online, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.

bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.

Original guideline publication (December 2013):